Methotrexate hydrate
SIGMA/06563 - ≥99.0% (sum of enantiomers, HPLC)
Synonym: 4-
CAS Number: 133073-73-1
Empirical Formula (Hill Notation): C20H22N8O5 · xH2O
Molecular Weight: 454.44 (anhydrous basis)
EC Number: 200-413-8
MDL Number: MFCD00150847
Linear Formula: C20H22N8O5 · xH2O
Product Type: Chemical
assay | ≥99.0% (sum of enantiomers, HPLC) |
biological source | synthetic |
form | powder or crystals |
impurities | ≤0.1% sulfated ash |
InChI | 1S/C20H22N8O5.H2O/c1-28(9 |
InChI key | FPJYMUQSRFJSEW-ZOWNYOTGSA |
mp | 185-204 °C |
optical activity | [α]/D +21.0±2.0° |
Quality Level | 200 |
SMILES string | [H]O[H].CN(Cc1cnc2nc(N)nc |
solubility | water: insoluble |
storage temp. | −20°C |
Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites. |
Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis. |
Other Notes: | Folic acid antagonist. Potent inhibitor of dihydrofolate reductase. |
Symbol | GHS06,GHS08 |
Signal word | Danger |
Hazard statements | H301 - H315 - H319 - H341 - H360D |
Precautionary statements | P201 - P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 |
Hazard Codes | T |
Risk Statements | 46-61-25-36/38 |
Safety Statements | 53-26-36-45 |
RIDADR | UN 1544PSN1 6.1 / PGIII |
WGK Germany | WGK 3 |
Purity | ≥99.0% (sum of enantiomers, HPLC) |
mp | 185-204 °C |
Storage Temp. | −20°C |
UNSPSC | 12352202 |